| ASSET | QUARTER | % RETURN |
|---|---|---|
Altimmune (ALT) | Q4 2023 | 326.14% |
Porch (PRCH) | Q4 2023 | 294.87% |
Gyre Therapeutics (GYRE) | Q4 2023 | 249.52% |
Absci (ABSI) | Q4 2023 | 218.18% |
Pulse Biosciences (PLSE) | Q4 2023 | 202.97% |
Esperion Therapeutics (ESPR) | Q4 2023 | 199% |
MoneyLion (ML) | Q4 2023 | 196.27% |
Eyepoint Pharmaceuticals (EYPT) | Q4 2023 | 189.24% |
Byrna Technologies (BYRN) | Q4 2023 | 184% |
Autolus Therapeutics (AUTL) | Q4 2023 | 175.21% |
Honest (HNST) | Q4 2023 | 166.13% |
Torrid (CURV) | Q4 2023 | 162.27% |
Frequency Therapeutics (KRRO) | Q4 2023 | 159.08% |
Bitfarms (BITF) | Q4 2023 | 155.26% |
Aveanna Healthcare (AVAH) | Q4 2023 | 127.12% |
Triumph (TGI) | Q4 2023 | 117.02% |
Sky Harbour (SKYH) | Q4 2023 | 115.14% |
Xometry (XMTR) | Q4 2023 | 111.73% |
Arvinas (ARVN) | Q4 2023 | 111.4% |
Loandepot (LDI) | Q4 2023 | 107.06% |
CVRx (CVRX) | Q4 2023 | 106.98% |
Tourmaline Bio (TRML) | Q4 2023 | 106.8% |
GigaCloud Technology Inc Class A Ordinary Shares (GCT) | Q4 2023 | 105.56% |
OppFi (OPFI) | Q4 2023 | 98.45% |
Lendingtree (TREE) | Q4 2023 | 95.99% |
Small-cap stocks are treated as having a market cap between $300M and $2B.
